From this point of view, IL-23 inhibitors were tried for treatment of RA, but use of guselkumab, a human IgG1 antibody against the p19 subunit of IL-23, did not lead to significant improvement [37]. The gene discussed is IL23A; the disease is rheumatoid arthritis.